Company Overview - LifeMD (NASDAQ: LFMD) has a unique corporate structure, originally founded as ImmuDyne in 1994 and going public in 2001, later rebranding to Conversion Labs in 2018 before adopting its current name [1] Investment Approach - The investment strategy focuses on a holistic approach that incorporates both top-down and bottom-up valuation techniques, emphasizing the importance of detailed company aspects such as capital structure and debt covenants in equity valuation [1]

Core Insights - LifeMD, Inc. is a leading provider of virtual primary care services, offering telemedicine and access to various healthcare services across more than 200 conditions [1][2] - The company will participate in two investor conferences in June, focusing on topics related to consumer and enterprise healthcare solutions [2] Company Overview - LifeMD provides a vertically integrated digital care platform, a 50-state affiliated medical group, and a 22,500-square-foot affiliated pharmacy [1] - The services offered include primary care, men's and women's health, weight management, and hormone therapy [1] Upcoming Events - Management will participate in the BTIG Obesity Health Forum on June 18, discussing "Direct to Consumer vs. Direct to Enterprise" [2] - The company will also be present at the Truist Securities Healthcare Disruptors & Digital Health Conference on June 24-25, with a panel discussion on "Tailored Approach to Weight Loss Solutions" [2]

Core Insights - LifeMD (NASDAQ: LFMD) has seen a price increase of approximately 46% since the last article published nearly a year ago, indicating positive market performance and investor interest in the company's Weight Management Program [1]. Company Overview - LifeMD is focused on innovative healthcare solutions, particularly in the realm of weight management, which is expected to influence its profitability timeline [1]. Investment Opportunities - The article highlights the potential for LifeMD's Weight Management Program to serve as a catalyst for future growth and profitability, suggesting that investors may find opportunities in this area [1].

Core Insights - LifeMD, Inc. has launched a limited-time introductory bundle for new self-pay patients, offering Wegovy at a discounted price of $199 along with access to its virtual weight management program for a total first-month cost of $299 [1][2] - The collaboration with Novo Nordisk enhances LifeMD's ability to provide branded GLP-1 medications through a fully integrated care experience, catering to the increasing number of self-pay patients seeking FDA-approved treatments [2][4] - The program will cost $599 per month starting from the second month, with no long-term commitment required [3] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine, laboratory, and pharmacy services across more than 200 conditions, including weight management [6] - The company utilizes a vertically integrated platform, which includes a 50-state medical group and national diagnostic lab partnerships, to ensure a seamless experience from consultation to ongoing support [4][6] Product Offering - Wegovy is the first GLP-1 therapy approved in the U.S. for chronic weight management and cardiovascular risk reduction in adults with obesity, available in an injector pen by prescription for eligible LifeMD patients [5]

Company Overview - LifeMD, Inc. is a leading provider of virtual primary care services, offering telemedicine, laboratory and pharmacy access, and specialized treatment for over 200 conditions [1] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to enhance access to high-quality and affordable care [1] Investor Engagement - Management will participate in several investor conferences in May, including the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, the B. Riley Securities 25th Annual Institutional Investor Conference on May 21-22, and the Craig-Hallum 22nd Annual Institutional Investor Conference on May 28 [2] - At these conferences, management will hold one-on-one meetings with investors and present a corporate overview [2]

Core Viewpoint - LifeMD, Inc. reported quarterly earnings of $0.01 per share, exceeding the Zacks Consensus Estimate of a loss of $0.04 per share, marking a significant improvement from a loss of $0.19 per share a year ago, resulting in an earnings surprise of 125% [1] Financial Performance - LifeMD posted revenues of $65.7 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 5.20%, compared to revenues of $44.14 million in the same quarter last year [2] - Over the last four quarters, the company has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - LifeMD shares have increased approximately 52.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $64.9 million, and for the current fiscal year, it is $0.06 on revenues of $267.95 million [7] Industry Outlook - The Medical Services industry, to which LifeMD belongs, is currently ranked in the top 25% of over 250 Zacks industries, indicating a favorable outlook [8]

LifeMD (LFMD) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Justin Schreiber - Chairman & CEOMarc Benathen - CFODavid Larsen - Managing DirectorSteve Dechert - AVP Conference Call Participants Sarah James - AnalystSteven Valiquette - MD & Senior Equity Research Analyst - Covering Health Care Technology & DistributionYi Chen - Managing Director & Senior AnalystAnderson Schock - Research Analyst Operator Good afternoon. Thank you for joining us today to discuss LifeMD's results for the f ...

Telehealth Performance - Telehealth revenue increased by 70% for the three months ended March 31, 2025, compared to the same period in 2024, with approximately 86% of total revenue coming from recurring subscriptions[133]. - Telehealth revenue accounted for 79.85% of total revenue, increasing to approximately $52.5 million, while WorkSimpli revenue remained consistent at approximately $13.2 million, representing 20.15% of total revenue[144]. - LifeMD's telehealth platform integrates a 50-state medical group and a nationwide pharmacy network, enhancing patient care delivery[130]. Patient Engagement - LifeMD currently serves approximately 291,000 active patient subscribers and has helped over 1,191,000 customers since inception[130]. - The GLP-1 Weight Management Program has grown to approximately 85,000 patient subscribers as of March 31, 2025, following its launch in April 2023[137]. - Rex MD has served more than 638,000 customers and patients to date, focusing on men's health needs[142]. Financial Performance - Total revenue for the three months ended March 31, 2025, was approximately $65.7 million, an increase of 49% compared to $44.1 million for the same period in 2024, driven by a 70% increase in telehealth revenue[144]. - Gross profit increased by approximately 44% to $57.1 million, with gross profit as a percentage of revenues decreasing to approximately 86.84% from 89.58% year-over-year[146]. - Operating income for the three months ended March 31, 2025, was approximately $2.5 million, a significant improvement from a loss of $6.2 million in the same period in 2024[144]. - Net income for the three months ended March 31, 2025, was approximately $1.9 million, compared to a net loss of $6.6 million for the same period in 2024[144]. Expenses and Cash Flow - Total expenses for the three months ended March 31, 2025, were approximately $54.5 million, an increase of 19% compared to $45.7 million for the same period in 2024[147]. - Net cash provided by operating activities was approximately $3.1 million for the three months ended March 31, 2025, down from $5.2 million in the same period in 2024[151]. - The Company has the ability to curtail expenses if necessary, contributing to its positive cash flow outlook[158]. Capital and Investments - The Company utilized approximately $2.9 million in investing activities, primarily for capitalized software costs of approximately $2.7 million[152]. - As of March 31, 2025, there was $19.0 million outstanding under the Avenue Facility, which provides a total credit facility of up to $40 million[156]. - The Company has $53.3 million available under the At Market Issuance Sales Agreement, part of the $150.0 million available under the 2024 Shelf[158]. - The Company received $10 million from Medifast to support collaboration, with $5 million paid at closing on December 12, 2023, and the remaining $5 million paid in installments[158]. - The Company issued 1,224,425 shares in a private placement to Medifast's subsidiary at a price of $8.1671 per share, raising approximately $10 million[159]. Future Outlook - The Company expects to have sufficient cash over the next 12 months due to continued revenue strengthening, reduced losses, and improved operational efficiencies[158]. - The Company anticipates an improvement in its cash burn rate and positive operating cash flows during the three months ended March 31, 2025[158]. - The overall market value of the telehealth industry is expected to drive interest in the Company, evidenced by the collaboration with Medifast[158]. Strategic Initiatives - The company plans to expand insurance acceptance to over 60 million Medicare beneficiaries nationwide by the end of Q2 2025[132]. - The company executed integration with LillyDirect's pharmacy provider to streamline access to obesity treatment for eligible patients[141]. - LifeMD's mission is to empower healthier lives by increasing access to high-quality virtual and in-home healthcare[131]. Accounting and Compliance - The Company is evaluating the impact of recent accounting standards updates on its consolidated financial statements[163][164].

LifeMD (LFMD) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon. Thank you for joining us today to discuss LifeMD's results for the first quarter ended 03/31/2025. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer and Mark Benethen, Chief Financial Officer. Following management's prepared remarks, we will open the call for a question and answer session. Before we begin, I would like to remind everyone that during this call, the company will make a number ...

[First Quarter 2025 Results](index=1&type=section&id=First%20Quarter%202025%20Results) LifeMD achieved its first-ever GAAP profitability in Q1 2025, driven by strong telehealth revenue growth and strategic initiatives, leading to raised full-year guidance [Management Commentary](index=1&type=section&id=Management%20Commentary) Management reported first-ever GAAP profitability in Q1 2025, driven by strong weight management performance and strategic initiatives, leading to raised full-year guidance - Achieved its first-ever quarter of **GAAP profitability**, driven by strong performance in its weight management program and expansion across all service areas[3](index=3&type=chunk) - Strategic collaborations with LillyDirect and NovoCare make LifeMD the only U.S. telehealth provider offering synchronous care and cash-pay access to both Wegovy and Zepbound[4](index=4&type=chunk) - Telehealth revenue grew **70% year-over-year**, and telehealth adjusted EBITDA increased to **$5.3 million** from a loss of $1.3 million in the prior-year period[5](index=5&type=chunk) - Announced key hires in mental and hormonal health and acquired assets in behavioral and women's health to address significant unmet clinical needs[4](index=4&type=chunk) [First Quarter Financial & Operational Highlights](index=1&type=section&id=First%20Quarter%20Financial%20%26%20Operational%20Highlights) Q1 2025 saw total revenues grow 49% to $65.7 million, driven by a 70% telehealth revenue surge, achieving the company's first GAAP net income of $0.6 million Q1 2025 Key Financial Metrics (vs. Q1 2024) | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenues | $65.7 million | $44.1 million | +49% | | Telehealth Revenue | $52.5 million | $30.8 million | +70% | | GAAP Net Income | $0.6 million | ($7.5 million) | N/A | | Diluted EPS | $0.01 | ($0.19) | N/A | | Adjusted EBITDA | $8.7 million | $0.1 million | +$8.6M | | Telehealth Adjusted EBITDA | $5.3 million | ($1.3 million) | +$6.6M | Q1 2025 Key Performance Metrics (Subscribers) | Subscriber Metric | Q1 2025 | Q1 2024 | Y-o-Y Growth | | :--- | :--- | :--- | :--- | | Telehealth Active Subscribers | 290,660 | 237,790 | 22% | | WorkSimpli Active Subscribers | 158,265 | 166,351 | -5% | | **Total Active Subscribers** | **448,925** | **404,141** | **11%** | - Cash on hand was **$34.4 million** as of March 31, 2025[10](index=10&type=chunk) [Financial Guidance](index=2&type=section&id=Financial%20Guidance) LifeMD raised its full-year 2025 revenue and adjusted EBITDA guidance, reflecting confidence in continued strong performance for Q2 2025 [Q2 2025 Guidance](index=2&type=section&id=Q2%202025%20Guidance) For the second quarter of 2025, the company projects total revenues between $65 million and $67 million and adjusted EBITDA in the range of $7 million to $9 million Q2 2025 Guidance | Metric | Guidance Range | | :--- | :--- | | Total Revenues | $65M - $67M | | Telehealth Revenue | $52M - $53M | | Adjusted EBITDA | $7M - $9M | | Telehealth Adjusted EBITDA | $4M - $6M | [Full-Year 2025 Guidance](index=2&type=section&id=Full-Year%202025%20Guidance) The company has raised its full-year 2025 guidance, with total revenues now expected between $268 million and $275 million, and adjusted EBITDA projected in the range of $31 million to $33 million Updated Full-Year 2025 Guidance | Metric | New Guidance Range | Previous Guidance Range | | :--- | :--- | :--- | | Total Revenues | $268M - $275M | $265M - $275M | | Telehealth Revenue | $208M - $213M | $205M - $213M | | Adjusted EBITDA | $31M - $33M | $30M - $32M | | Telehealth Adjusted EBITDA | Forecast to exceed $21M | Approx. $20M | [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) The consolidated financial statements detail LifeMD's balance sheet, income statement, and cash flow performance, reflecting improved profitability and financial position in Q1 2025 [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, LifeMD reported total assets of $73.6 million, decreased total liabilities to $74.0 million, and improved its stockholders' deficit to $0.4 million Balance Sheet Summary (in millions) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $34.4 | $35.0 | | Total Current Assets | $50.0 | $48.7 | | **Total Assets** | **$73.6** | **$72.5** | | **Liabilities & Equity** | | | | Total Current Liabilities | $60.9 | $60.3 | | Total Liabilities | $74.0 | $76.5 | | Total Stockholders' Equity (Deficit) | ($0.4) | ($4.0) | | **Total Liabilities & Equity** | **$73.6** | **$72.5** | [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) Q1 2025 saw a significant turnaround with $0.6 million net income attributable to common stockholders, driven by a 49% revenue increase to $65.7 million and a shift to operating income Statement of Operations Summary (Q1 2025 vs Q1 2024, in millions) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Total Revenues, Net | $65.7 | $44.1 | | Gross Profit | $57.1 | $39.5 | | Operating Income (Loss) | $2.5 | ($6.2) | | Net Income (Loss) Attributable to Common Stockholders | $0.6 | ($7.5) | | Diluted EPS | $0.01 | ($0.19) | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, the company generated $3.1 million in cash from operating activities, used $2.9 million in investing, and ended the quarter with $34.4 million in cash Cash Flow Summary (Q1 2025 vs Q1 2024, in millions) | Cash Flow Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $3.1 | $5.2 | | Net cash used in investing activities | ($2.9) | ($2.2) | | Net cash used in financing activities | ($0.8) | ($1.0) | | **Net (decrease) increase in cash** | **($0.6)** | **$2.0** | | **Cash at end of period** | **$34.4** | **$35.1** | [Non-GAAP Financial Measures](index=8&type=section&id=Non-GAAP%20Financial%20Measures) LifeMD presents non-GAAP financial measures, including Adjusted EBITDA for consolidated and segment results, to provide a clearer view of core business performance by excluding specific non-recurring or non-cash items [Reconciliation of GAAP Net Income to Consolidated Adjusted EBITDA](index=9&type=section&id=Reconciliation%20of%20GAAP%20Net%20Income%20to%20Consolidated%20Adjusted%20EBITDA) Consolidated Adjusted EBITDA significantly improved to $8.7 million in Q1 2025 from $0.1 million in Q1 2024, reconciled from GAAP net income with adjustments for non-cash items Consolidated Adjusted EBITDA Reconciliation (Q1 2025 vs Q1 2024, in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net income (loss) attributable to common shareholders | $608 | ($7,545) | | Adjustments (Depreciation, Stock Comp, etc.) | $8,051 | $8,653 | | **Consolidated Adjusted EBITDA** | **$8,659** | **$108** | [Reconciliation of Telehealth Operating Income to Telehealth Adjusted EBITDA](index=10&type=section&id=Reconciliation%20of%20Telehealth%20Operating%20Income%20to%20Telehealth%20Adjusted%20EBITDA) Telehealth segment's Adjusted EBITDA swung to a positive $5.3 million in Q1 2025 from a $1.3 million loss in Q1 2024, reconciled from operating income with key adjustments Telehealth Adjusted EBITDA Reconciliation (Q1 2025 vs Q1 2024, in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Telehealth operating income (loss) | $387 | ($6,620) | | Adjustments (Depreciation, Stock Comp, etc.) | $4,919 | $5,289 | | **Telehealth Adjusted EBITDA** | **$5,306** | **($1,331)** | [Reconciliation of WorkSimpli Operating Income to WorkSimpli Adjusted EBITDA](index=10&type=section&id=Reconciliation%20of%20WorkSimpli%20Operating%20Income%20to%20WorkSimpli%20Adjusted%20EBITDA) WorkSimpli segment's Adjusted EBITDA more than doubled to $3.4 million in Q1 2025 from $1.4 million in Q1 2024, reconciled from operating income with adjustments WorkSimpli Adjusted EBITDA Reconciliation (Q1 2025 vs Q1 2024, in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | WorkSimpli operating income | $2,156 | $449 | | Adjustments | $1,197 | $990 | | **WorkSimpli Adjusted EBITDA** | **$3,353** | **$1,439** |